Simon D Morgan
UK Guide 2025
Band 1 : Corporate/M&A: £100-800 million
Band 1
About
Provided by Simon D Morgan
Work Highlights
Blue Prism, the robotic process automation software business, on its USD 1.65bn recommended offer from SS&C, following the USD 1.5bn recommended offer made for it by US private equity firm, Vista.
M&C Saatchi, the international marketing agency, on its successful defence of the hostile GBP 264m offer made for it by AdvancedAdvT and on the competitive GBP 310m offer made for it by Next15 Communications Group.
BBC Studios, on its GBP 255m acquisition of the ITV Group’s 50% interest in BritBox International, the leading British content TV streamer operating in nine countries.
FremantleMedia Group, on its acquisition of Asacha Media Group, a pan European TV production Group with TV production companies in France, Italy and the UK, on its acquisition of controlling interests in Element Pictures, 72 Films and Wildstar Films and on a series of investments in TV production companies.
BAE Systems on the sale of NetReveal, its financial crime detection business division, to SymphonyAI.
Gigaclear, and its principal shareholder, a fund advised by Infracapital, on an up to GBP 420m equity investment made by funds managed by Equitix.
Rank Group on its GBP 115m offer for online gaming operator, Stride Gaming.
Blue Prism on a GBP 100m equity placing in 2019 and a GBP 100m equity placing in 2020 and Rank Group on a GBP 70m equity placing in 2020.
ParentPay, a leading provider of education technology, on the acquisition by Montagu Private Equity, of a minority interest including the sale by Montagu Private Equity of ESS, an education solutions softare business, to ParentPay.
Syncona, the UK based life science investor, on its investment in a series of life science companies and on the USD 476m sale of Blue Earth Diagnostics, a developer of molecular imaging agents including one involved in the targeting of prostate cancer cells, to Bracco Imaging.
Freeline Therapeutics, a life science company focused on developing curative gene therapies for chronic systemic diseases, on a USD 120m Series C financing including funding from Syncona, Novo Holdings, Eventide Asset Management and Wellington Management Company.
Delancey advised fund, DV4, and management, on the sale of db Symmetry (dbS) to Tritax Big Box REIT valuing dbS at GBP 370m.
Practice Areas
Simon Morgan is a partner in the Corporate/M&A Team at CMS London. Simon has over 30 years' experience of advising on corporate transactional matters, advising clients across a number of business sectors including Lifesciences, communications and technology.
Clients include established domestic and international companies, public bodies, growing businesses, investment groups and professional intermediaries.
Education
Pembroke College, Cambridge
MA Law
1984
Law Society Finals, England and Wales
1985
Admitted as a solicitor in England and Wales
1987
Chambers Review
UK
Simon Morgan is able to draw on deep experience when assisting clients in sophisticated corporate transactions. He acts for a diverse client base and is well versed in deals in the technology, life sciences and technology sectors, among others.
Strengths
Provided by Chambers
"Simon is a very trustworthy and technically strong lawyer. He makes himself available when he needs to be, and we have a strong working relationship with him."
"Simon Morgan is very good and gives very sensible advice."
"Simon is a very trustworthy and technically strong lawyer. He makes himself available when he needs to be, and we have a strong working relationship with him."
"Simon Morgan is very good and gives very sensible advice."